Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The conversation is about the safety of using a dermastamp at 0.25mm depth twice a day when applying Minoxidil. The user seeks confirmation on whether this practice is safe despite mixed opinions.

A 21-year-old individual questioning the safety and potential side effects of using Dutasteride for hair loss, after Finasteride and RU58841 had limited effect. The responses vary, with some users suggesting it's safe and others advising to check hormone levels before proceeding.

Concerns about the long-term safety of Minoxidil and Finasteride for hair loss, with suggestions to weigh risks and consider cost-effective options like cutting higher-dose pills. Some users prefer Minoxidil due to perceived safety.

The conversation is about the safety and side effects of using dutasteride in mesotherapy for hair loss. The user is skeptical about the lack of reported side effects and seeks anecdotal experiences.

Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

Avoid buying unregulated Thai oral minoxidil online due to quality and safety concerns; instead, get a prescription for legitimate, tested minoxidil from a pharmacy. Some users also use finasteride and ketoconazole for hair loss treatment.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

The conversation discusses the variability in effectiveness and safety of generic finasteride from different manufacturers, with some generics potentially containing impurities. Users shared their experiences with various brands, questioning if different brands affect hair loss treatment outcomes.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

A British man's death at a Turkish hair transplant clinic raised safety concerns about such clinics. Users discussed risks of cheaper clinics and suggested alternatives like Thailand, Korea, and Colombia.

The user is considering reducing RU58841 dosage from 100mg to 17.5mg for long-term safety due to brain fog issues from finasteride. They apply RU58841 only to the front of the scalp where thinning occurs.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.

Mixing finasteride pills with stemoxydine is not recommended due to potential solubility and safety issues. It's advised to consult a healthcare provider for professionally formulated topical finasteride products.

Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.

KX-826 is considered effective for hair maintenance, with better safety research than RU58841, but lacks positive anecdotes. RU58841 is seen as potentially stronger, but concerns exist about systemic effects; combining anti-androgens with 5AR inhibitors is suggested for better results.

The user seeks to maintain hair without using finasteride or minoxidil due to side effects and safety concerns. Suggestions include oral minoxidil, microneedling, ketoconazole shampoo, and a protein-rich diet, but maintaining hair without a DHT blocker is unlikely.

The user is using finasteride for hair loss and is frustrated with shedding but plans to add oral minoxidil for convenience and safety. There are concerns about using topical minoxidil around pets.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

PP405 is considered a potential alternative to minoxidil and finasteride, but its effectiveness and safety are still uncertain. Many users suggest sticking with proven treatments like finasteride and minoxidil due to the lack of long-term data on PP405.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

OP is considering using a keratin gel to improve hair quality and is concerned about its safety and visual impact on a slightly balding crown. Users discuss shampoo frequency, with some suggesting less frequent use for better hair health, but OP prefers regular shampoo and conditioner for silky hair.

Microneedling with exosomes is being considered for hair regrowth, but concerns exist about their effectiveness and safety, especially since exosomes degrade quickly and lack FDA approval. The user is seeking alternatives for non-responders to minoxidil and dutasteride, as exosomes may not provide additional benefits.